Elranatamab

Overview

Elranatamab is a B-cell Maturation Antigen (BCMA)-CD3 bispecific antibody being tested in multiple myeloma.

SparkCures ID 302
Developed By Pfizer
Generic Name Elranatamab
Additional Names PF-06863135
Treatment Classifications
Treatment Targets
Tags

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Verified
Phase 1 / 2 Study of Elranatamab in People with Relapsed/Refractory Multiple Myeloma
MAGNETISMM-9
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified
Phase 1 / 2 Study of Elranatamab in People with Relapsed/Refractory Multiple Myeloma
MAGNETISMM-9
View Trial
Verified
Phase 1/2 Clinical Trial Evaluating the Safety, Effectiveness and Best Dose of Elranatamab Combined with Different Anti-Cancer Therapies in Participants with...
MAGNETISMM-4
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
View Trial
Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Published Results

Pfizer Presents First Data from Planned Interim Analysis of Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab Under Investigation for Relapsed/Refractory Multiple Myeloma

June 05, 2022

In this interim analysis, safety and efficacy was analyzed in 94 patients who had received at least one dose of elranatamab (Cohort A – BCMA-naïve) as of the data cutoff on March 23, 2022. Patients received subcutaneous (SC) elranatamab 76 mg weekly (QW) with a 2-step-up priming dose regimen administered during the first week. With a median follow up of 3.71 months, initial efficacy results showed that the objective response rate for elranatamab was 60.6%. As of the data cut-off, 89.5% of objective responders were ongoing without confirmed progression or death.

Read More

Resources